Lifeward Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lifeward Ltd. (LFWD) on August 31, 2026. The filing discloses significant changes to the Company's executive leadership and Board of Directors effective August 31, 2026, and September 1, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CEO: Mark Grant resigned as President, Chief Executive Officer, and Board member effective August 31, 2026. The departure was not due to any disagreement with the Company.
- CEO Compensation: Mr. Grant will receive no cash severance. He will forfeit all unvested equity awards. He will serve as a Senior Advisor until September 30, 2026, for a consulting fee of $40,000.
- Appointment of Interim CEO: Josh Hexter was appointed Interim CEO effective September 1, 2026. He is currently the Chief Operating and Business Officer of Oramed Pharmaceuticals Inc., the Company's controlling shareholder.
- Interim CEO Compensation: Mr. Hexter will receive a gross monthly base salary of NIS 100,000 plus a NIS 5,000 commuting allowance (or company car). His terms are not more favorable than Mr. Grant's and require shareholder approval at the next general meeting.
- Appointment of CFO: Rami Aviram was appointed Chief Financial Officer, effective November 1, 2026, succeeding Almog Adar (departing September 30, 2026).
- CFO Compensation: Mr. Aviram will receive a gross monthly base salary of NIS 70,000 plus a NIS 5,000 commuting allowance (or company car).
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. The primary risk disclosed relates to the transition of leadership and the reliance on an interim CEO who maintains a reduced role at the controlling shareholder, Oramed Pharmaceuticals Inc. The Company intends to appoint an interim CFO to bridge the gap between Mr. Adar's departure and Mr. Aviram's start date.
Investor Verification Checklist
- Verify the terms of the Separation and Consulting Agreements with Mark Grant in the upcoming Form 10-Q for the quarter ending September 30, 2026.
- Confirm the shareholder approval status of Josh Hexter's employment agreement at the next general meeting of shareholders.
- Monitor the appointment of the interim CFO to ensure continuity between September 30, 2026, and November 1, 2026.
- Review the relationship between the new Interim CEO and the controlling shareholder, Oramed Pharmaceuticals Inc., for potential conflicts of interest.